Atlantic International

Atlantic International EBITDA per Share

The EBITDA per Share of Atlantic International (ATLN) as of Oct 27, 2026 is -0.90 USD. In the previous year, EBITDA per Share was -0.32 USD — a change of 184.42% (lower).

EBITDA per Share

-0.90USD

YoY

184.42%

Last updated:

EBITDA per Share of Atlantic International is 2025 -0.90 USD. EBITDA per Share of Atlantic International was 2024 -0.32 USD. It decreases by 184.42% lower compared to the previous year.

The Atlantic International EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-0.11 USD
Jan 1, 2019
-0.11 USD
Jan 1, 2020
-0.04 USD
Jan 1, 2021
-1.65 USD
Jan 1, 2022
0.28 USD
Jan 1, 2023
-0.14 USD
Jan 1, 2024
-0.32 USD
Jan 1, 2025
-0.90 USD
The Atlantic International EBITDA per Share history
YEAREBITDA per ShareYoY
-0.90USD+184.42%
-0.32USD+133.50%
-0.14USD-149.25%
0.28USD-116.73%
-1.65USD+3,602.38%
-0.04USD-58.55%
-0.11USD-4.58%
-0.11USD+57.24%
-0.07USD+282.21%
-0.02USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Atlantic International Stock analysis

What does Atlantic International do? SeqLL Inc. develops and sells genetic analysis technologies, focusing on its True Single Molecule Sequencing (tSMS) platform. The company's products enable researchers and clinicians to perform DNA and RNA sequencing without complex sample manipulation, analyzing billions of single molecules per experiment. Its tSMS platform integrates fluorescence-based optical detection with microfluidics and thermal control systems. The primary buyers are research institutions and life sciences companies seeking advanced sequencing solutions for scientific research and development. SeqLL Inc. generates revenue through the sale of its sequencing technologies and related research services. The company's intellectual property and scientific assets across multiple omics fields support its product offerings. The target market includes academic researchers, biotechnology firms, and clinical laboratories requiring high-precision genomic analysis tools. The firm's technology allows for reproducible data generation, appealing to customers focused on accuracy in genetic research. The company's business model centers on developing and commercializing proprietary sequencing technology. Its tSMS platform differentiates itself by eliminating the need for complex sample preparation, offering a streamlined approach to nucleic acid detection. SeqLL Inc. serves the life sciences industry by providing tools that accelerate research in genomics and molecular biology. The firm's products are designed to support both basic research and applied clinical applications in genetic analysis. Atlantic International is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Atlantic International stock

EBITDA per Share of Atlantic International is -0.90 USD in 2025.

EBITDA per Share of Atlantic International changed from -0.32 USD to -0.90 USD, representing a 184.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Atlantic International since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Atlantic International

All Key Metrics — Atlantic International